Overall Survival Benefit of Adding Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumour Proportion Score of more than or equal to 50% Predicted by dNLR-Based Score
Pembrolizumab (P) was a common first-line therapeutic option for advanced non-small cell lung...
Read More